Please login to the form below
Seroquel
This page shows the latest Seroquel news and features for those working in and with pharma, biotech and healthcare.
AstraZeneca divests Seroquel rights to focus on key therapy areas
AZ will continue to manufacture and supply Seroquel and Seroquel XR to Cheplapharm during a transition period. ... In 2018, Seroquel reported sales of $36m in the markets included in this agreement, while Seroquel XR generated $79m.
Latest news
-
Daily Brief: Italy in turmoil, Pharma attacks Europe's generics move and more
AstraZeneca for rights to its former blockbuster Seroquel and Seroquel XR in international markets. ... It believes it can oversee a major increase in Seroquel sales in China.
-
AZ expects return to growth this year after 2017 decline
to $2.6bn, although the cumulative effect of patent expiries - which also affect antipsychotic Seroquel XR (quetiapine) and gastrointestinal drug Nexium (esomeprazole) - are starting to dissipate.
-
AZ CEO says company’s renaissance is on track
for cholesterol drug Crestor (rosuvastatin) and antipsychotic Seroquel XR (quetiapine).
-
Patent cliff losses set to cost pharma $65bn by 2019
GlobalData analyst Adam Dion said: “AZ, CNS segment has been bleeding sales as a result of the company losing its patent on Seroquel (quetiapine), a treatment for bipolar disorder.
-
Abilify Maintena launches in Europe
Zyprexa (olanzapine) and AstraZeneca's Seroquel (quetiapine) - now available generically.
More from news
Approximately 3 fully matching, plus 73 partially matching documents found.
Latest Intelligence
-
Who tops the pharma list?
For example, patents for Seroquel (AstraZeneca - 2011 revenues of $5.8bn), Zyprexa (Eli Lily - $4.6bn) and Concerta (J&J - $1.3bn) had all expired by May 2012.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- MHRA to introduce new UK clinical trials framework
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- PMGroup announces launch of new recruitment platform PharmaRole
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- BioNTech reveals plans to spend about €1bn more on research and development this year
- AstraZeneca’s mild combination asthma reliever approved in UK
- Virtual Patient Engagement Program: A Customer Story
- Putting Skin in the Game at AAD 2023
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- Sanofi/Regeneron’s Dupixent approved by EC for atopic dermatitis in children
- Inizio appoints Stefanie Christmas as global head of DE&I
PMHub
Accession
Accession was a born from a passion and a vision. A passion to harness the power of market access to...
Latest intelligence
- Virtual Patient Engagement Program: A Customer Story
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
- Humancomms for humancare?
- Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
